JPWO2021243172A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021243172A5
JPWO2021243172A5 JP2022571787A JP2022571787A JPWO2021243172A5 JP WO2021243172 A5 JPWO2021243172 A5 JP WO2021243172A5 JP 2022571787 A JP2022571787 A JP 2022571787A JP 2022571787 A JP2022571787 A JP 2022571787A JP WO2021243172 A5 JPWO2021243172 A5 JP WO2021243172A5
Authority
JP
Japan
Prior art keywords
rna replicon
recombinant rna
item
cancer
coding region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571787A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528300A (ja
JP2023528300A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034787 external-priority patent/WO2021243172A1/en
Publication of JP2023528300A publication Critical patent/JP2023528300A/ja
Publication of JPWO2021243172A5 publication Critical patent/JPWO2021243172A5/ja
Publication of JP2023528300A5 publication Critical patent/JP2023528300A5/ja
Withdrawn legal-status Critical Current

Links

JP2022571787A 2020-05-29 2021-05-28 封入されたrnaレプリコンおよび使用方法 Withdrawn JP2023528300A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032000P 2020-05-29 2020-05-29
US63/032,000 2020-05-29
PCT/US2021/034787 WO2021243172A1 (en) 2020-05-29 2021-05-28 Encapsulated rna replicons and methods of use

Publications (3)

Publication Number Publication Date
JP2023528300A JP2023528300A (ja) 2023-07-04
JPWO2021243172A5 true JPWO2021243172A5 (https=) 2024-06-04
JP2023528300A5 JP2023528300A5 (https=) 2024-06-04

Family

ID=78722848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571787A Withdrawn JP2023528300A (ja) 2020-05-29 2021-05-28 封入されたrnaレプリコンおよび使用方法

Country Status (8)

Country Link
US (1) US20230416308A1 (https=)
EP (1) EP4157456A4 (https=)
JP (1) JP2023528300A (https=)
KR (1) KR20230019450A (https=)
CN (1) CN115666722A (https=)
AU (1) AU2021281357A1 (https=)
CA (1) CA3180557A1 (https=)
WO (1) WO2021243172A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166783B (zh) 2018-10-09 2024-10-11 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
AU2023259636A1 (en) * 2022-04-29 2024-10-10 Elevatebio Technologies, Inc. Production of rna polynucleotides encoding picornavirus
WO2023223183A1 (en) * 2022-05-16 2023-11-23 Crispr Therapeutics Ag Picornaviral vectors for gene editing
EP4704872A2 (en) * 2023-05-05 2026-03-11 Mayo Foundation for Medical Education and Research Methods and materials for treating cancer
WO2025072371A2 (en) * 2023-09-27 2025-04-03 The General Hospital Corporation Highly active myeloid therapy
CN118460614B (zh) * 2024-07-05 2025-03-11 凌意(杭州)生物科技有限公司 一种腺相关病毒Cap蛋白的表达框
ES3058740A1 (es) * 2025-08-01 2026-03-12 Univ Valencia Politecnica Nanopartícula lipídica, composición farmacéutica y uso de la nanopartícula en el tratamiento del cáncer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040498A1 (en) * 2001-03-14 2003-02-27 Ansardi David Calvert Oncolytic RNA replicons
US20030077251A1 (en) * 2001-05-23 2003-04-24 Nicolas Escriou Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins
US20100129406A1 (en) * 2006-09-01 2010-05-27 Anza Therapeutics, Inc. Holin-enhanced vaccines and reagents, and methods of use thereof
JP6396891B2 (ja) * 2013-04-17 2018-09-26 新日本製薬株式会社 遺伝子改変コクサッキーウイルス
MA41506A (fr) * 2015-02-13 2017-12-19 Takeda Vaccines Inc Procédés de production de virus pour produire des vaccins
AU2018301701A1 (en) * 2017-07-14 2020-02-27 Elevatebio Technologies, Inc. Encapsulated polynucleotides and methods of use
EP3876951A1 (en) * 2018-11-06 2021-09-15 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy

Similar Documents

Publication Publication Date Title
JP7776176B2 (ja) 環状rnaを調製するための構築物及び方法
EP4141111A1 (en) Oncolytic virus vaccine and drug for treating tumors by combining oncolytic virus vaccine with immune cells
JP2004525855A5 (https=)
JPWO2020142725A5 (https=)
Zhao et al. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
JP2003511080A (ja) 免疫治療組成物調製用のレンチウイルスベクター
JPWO2019226941A5 (https=)
Kairuz et al. Advancing mRNA technologies for therapies and vaccines: An African context
CN118414426A (zh) 产生环状rna的单罐法
CN118556131A (zh) 用于蛋白质表达的mRNA及其模板
JP2005508610A (ja) 異種タンパク質の製造に有用なプラス鎖rnaウイルスゲノムに由来するレプリコン
JPWO2021243172A5 (https=)
EP4333892A1 (en) Chimeric antigen receptors and methods of use
JPWO2022150485A5 (https=)
FR2559159A1 (fr) Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues
JP2022536945A (ja) B型肝炎ウイルス(HBV)ワクチンおよびHBVを標的化するRNAiの組合せ
US20060088536A1 (en) Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
JP2024503000A (ja) 発現構築物およびその使用
KR100686356B1 (ko) 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제
JPWO2019158955A5 (https=)
EP4326879A2 (en) Drug-regulatable transcription factors
WO2025016031A1 (zh) 自扩增核酸分子及其应用
US20230272423A1 (en) Dna molecules producing custom designed replicating and non-replicating negative stranded rna viruses and uses there of
JPWO2021003348A5 (https=)
CA3255274A1 (en) Lipid nanoparticles including a Venezuelan equine encephalitis (VEE) replica and their uses